[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
申请人:Clark D. Jerry
公开号:US20050043309A1
公开(公告)日:2005-02-24
This invention relates to compounds of the formula 1
wherein G, D, A, Z, Q, X, Y, R
1
, and R
4
through R
7
are defined as in the specification, processes for preparing the same and intermediates used in making the same, and pharmaceutical compositions containing such compounds and their use in the treatment of central nervous system disorders and other disorders.
The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
substitution even in the presence of strong electron‐donating groups and enables de‐tert‐butylation required for the complete annulation. Also demonstrated is the applicability of the method to introduce five‐, six‐, and seven‐membered rings containing oxygen, whereas multiple annulations also open up a short synthetic path to ladder‐type O‐heteroacenes and oligodibenzofurans.